AUTHORS
Akram Abushamma, MD, Eno-obong Blessing Udoh, BS2, Carlos Bravo-Perez, MD3, Aashray Mandala, BS4, Akriti G Jain, MD, FACP5, Serhan Unlu, MD6, Mark David Orland, MD, PhD7, Zachary Brady, BS8, Carmelo Gurnari, MD,PhD9, Valeria Visconte, PhD10, Jaroslaw P. Maciejewski, MD, PhD, FACP11
AFFILIATIONS
1 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
2 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
3 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
4 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
5 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
6 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
7 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States, Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
8 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
9 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
10 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
11 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
ABSTRACT
Background. Acquired bone marrow failure syndromes (BMFS) are immune-mediated disorders characterized by cytopenias and include aplastic anemia (AA), pure red cell aplasia (PRCA), large granular lymphocyte leukemia (LGLL), and chronic idiopathic neutropenia (CIN). BMFS share T-cell and cytokine-mediated disruption of hematopoietic stem and progenitor cells. This disruption can impact B-cell development and therefore could potentially result in hypogammaglobulinemia. Small studies have associated BMFS with hypogammaglobulinemia (Mir et al, 1977; Bravo-Perez et al, 2025); however, the prevalence, clinical associations, and prognostic impact of hypogammaglobulinemia across these disorders remain unknown.
Methods. We conducted a large, single-center, cohort study of adult patients (aged ≥18 years) with acquired BMF (AA, PRCA, LGLL, or CIN) who underwent pretreatment immunoglobulin measurements (IgG, IgA, and IgM). Patients with inherited BMF, transplant recipients, or those with secondary causes of hypogammaglobulinemia were excluded. Any hypogammaglobulinemia was defined as a measurement below the 2.5th percentile of the general population using clinical laboratory reference at our institution (IgG < 717 mg/dL, or IgA < 78 mg/dL, or IgM < 53 mg/dL). The primary outcome was the prevalence of any hypogammaglobulinemia in acquired BMFS compared to the general population. The secondary outcome was the association of hypogammaglobulinemia with overall survival (OS), treatment response, and inborn errors of immunity (IEI). Whole exome sequencing (WES) and serial immunoglobulins were collected when available. Patients who received any treatment were classified as complete response (CR), partial response (PR), or no response (NR). OS was estimated using the Kaplan-Meier method with subgroup comparisons using the log-rank test. A multivariable Firth-penalized logistic regression adjusted for age, sex, ANC, hemoglobin, and platelets was used for mortality association in AA, with Benjamini–Hochberg correction.
Results. Of 891 patients with acquired BMFS, 551 were included (50.3% LGL, 34.8% AA, 8.3% PRCA, 6.5% CIN). The median age was 62 (47-71), 52.5% were males. The prevalence of any hypogammaglobulinemia was 35.8% (197/551), compared with 6.7% in the general population. Overall, IgM was the most prevalent subclass deficiency in 20.9% (115/551; 30% PRCA, 22% LGL, 19% CIN, 17% AA), followed by IgG 17.6% (97/551), and IgA 16% (88/551). At baseline, PRCA had the highest prevalence of any hypogammaglobulinemia, 54% (25/46), followed by LGL, 36% (99/277), CIN, 36% (13/36), and AA, 31% (60/192). During a median follow-up of 5.1 years (IQR, 2.1–9.8), 175 patients (32%) died. Any hypogammaglobulinemia was associated with a higher risk of mortality compared with no hypogammaglobulinemia (36% vs 28%; OR, 1.53; log-rank P=.025). After excluding patients with AA, the results were insignificant (P=.221). In AA, IgM deficiency was associated with ~4 times the odds of mortality (aOR 4.19, 95% CI, 1.82–10.01, FDR q=0.007). Among 434 patients who received treatment, hypogammaglobulinemia was not associated with treatment response. WES was available for 27% (76/277) of patients with LGL, of which 18% (14/76) carried high-confidence deleterious variants in genes associated with IEI. Hypogammaglobulinemia was more frequent among carriers than non-carriers (43% vs 29%). Among 301 patients with serial immunoglobulin measurement over a median interval of 4.3 years, 73% received immunosuppressive therapy (IST). All immunoglobulin levels declined significantly from baseline to follow-up (IgG: median Δ = −85 mg/dL, 63%, P<.001; IgM: median Δ = −11 mg/dL, P<.001, 61%; IgA: median Δ = −7 mg/dL, P=.027; 56% of patients).
Conclusions. In this large cohort of patients with acquired BMFS, the prevalence of any hypogammaglobulinemia was ~5 times that measured in the general population. The most common deficient subclass was IgM, and measurements <53 mg/dL were associated with higher odds of mortality. These findings suggest that acquired or inherited immunodeficiency manifested as hypogammaglobulinemia is part of the pathogenesis of a significant proportion of autoimmune (idiopathic) BMF as a primary process likely leading to immune dysregulation and compensatory maladaptive cellular immune responses.
DISCLOSURES
Akram Abushamma, MD: No relevant conflicts of interest to declare.